• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Monthly, March 2017

The CenterWatch Monthly, March 2017

March 1, 2017
CenterWatch Staff

Novo Nordisk, Servier, Otsuka, Teva among top sponsors

Sponsors have done a good job of main­taining, but not improving, the overall quality of their relationships with in­vestigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across sev­eral of the attributes sites identify as the most important for conducting a successful study. Leading sponsor companies have made strengthening their relationships with inves­tigative sites a top priority in recent years and have created a wide range of initiatives de­signed to incorporate investigator viewpoints into improving clinical development process­es and easing site burdens. The 2017 CenterWatch Global Investigative Site Survey suggests that investigators have raised their expectations for sponsor perfor­mance in providing better study support, good protocol design and easily accessible staff as in­vestigators face increasing compliance, regula­tory and financial pressures when conducting clinical trials.

Sites wrestle with protocol design complexity

The growing complexity of protocols is re­sulting in longer cycle times, rising costs and increased pressures on staff and patients throughout the clinical trial process. Tufts Center for the Study of Drug Develop­ment (CSDD) studies have found that the num­ber of endpoints, procedures and eligibility criteria of typical phase III protocols increased significantly during 2002-2012, and have con­tinued to grow. These factors combine to in­crease costs and burdens on research teams.

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing